Cristina Gálvez
Cristina Gálvez graduated in Biomedical Sciences from the University of Barcelona in 2014 and MSc in AIDS Pathogenesis and Treatment from Gimbernat – Autonomous University of Barcelona in 2015. Then she joined Dr. Javier Martinez-Picado’s team at IrsiCaixa, obtaining her PhD in Biochemistry, Molecular Biology and Biomedicine in 2021. During her PhD she focused her research on studying the mechanisms of HIV persistence and characterizing the viral reservoir in different patient cohorts. A year after completing her PhD, Cristina studied a Master’s Degree in Clinical Trial Monitoring and start working as a clinical research associate involved in international clinical research studies in cancer, nephrology and Alzheimer.
In 2023, Cristina came back to IrsiCaixa to work as a data manager.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.
Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.